Inversago Pharma

Leading the Way
in Peripheral CB1
Blockade
We Leverage the
Full Potential of
Peripherally-acting
CB1 Inverse Agonists

About Inversago Pharma

Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy.

The Peripheral CB1 Company

Targeting metabolic diseases in need of better adapted treatment options

Targeting metabolic diseases in need of better adapted treatment options

Inversago has the know-how, technology and clinical expertise to develop safe and potent inverse agonists of peripheral CB1 receptors to address a broad range of medical indications (conditions related to obesity such as Prader-Willi syndrome (PWS), liver diseases (NASH) or diabetes (type 1 diabetes and diabetic nephropathy)).

INV-101, our lead program focusing on PWS and NASH, is a peripherally-acting CB1 inverse agonist in clinical development. Our other candidate molecules targeting the peripheral CB1 pathway have also shown activity in several preclinical models.